Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCellAmp
- Development stage
- Preclinical
- Lead developer
- Ergon Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TCellAmp is a preclinical-stage small molecule developed by Ergon Pharmaceuticals designed to enhance the manufacturing and therapeutic efficacy of T-cell therapies, including Chimeric Antigen Receptor (CAR) T-cell therapies. The compound acts by amplifying the proliferative capacity of T cells, leading to improved growth rates and enhanced tumor-killing properties. It is primarily investigated for the treatment of hard-to-treat blood cancers and is utilized as a manufacturing additive to optimize the ex vivo expansion and quality of CAR-T cell products, potentially addressing challenges related to cell potency and persistence in refractory oncology settings.
Beyond the preview
Go deeper on TCellAmp.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCellAmp.